Purpose: Obesity has become a major public health concern worldwide, increasing the risk of T2DM. Growing evidence indicates gut microbiota dysbiosis is related to metabolic disorders. We aimed to firstly investigate the compositional and functional features of the gut microbiome between obesity with and without T2DM in the Chinese population. Methods: A total of 32 obese individuals accompanied with T2DM and 18 age and gender-matched obesity with normal glucose tolerance (NGT) were enrolled. Fecal samples were collected, and the gut microbiota profile was determined using the Illumina MiSeq platform based on V3-V4 bacterial 16S rRNA gene. Results: Compared with obesity- NGT, obesity-T2DM showed a significantly higher alpha diversity. Principal coordinates analysis based on both Bray-Curtis distance and weighted Unifrac revealed that the global microbial composition was significantly different between the two groups (P = 0.007 and P = 0.005, respectively). At the phylum level, Obesity-T2DM patients exhibited a significant decrease in Bacteroidetes, and a pronounced increase in Firmicutes. Regarding the genus level, Bacteroides and Escherichia-Shigella were found to increase considerably, while Prevotella_9 and Sutterella had an evident decrease in Obesity-T2DM. Furthermore, Spearman correlation analysis revealed that Prevotella_9 and Sutterella were negatively associated with HbA1c and fasting blood glucose. Conclusion: We found clear differences in the gut microbiota composition in obesity-T2DM compared with obesity-NGT. Obesity accompanied with T2DM may aggravate the obesity-associated gut microbiota, and gut microbiota is expected to be a promising novel intervention target for obese management. However, larger sample size and more in-depth taxonomic identification studies are warranted.
1 April 2024 in Diabetes, Metabolic Syndrome and Obesity
Background: Von Hippel-Lindau (VHL) syndrome is characterized by tumorous lesions affecting multiple organs. Pancreatic involvement in VHL syndrome can present as endocrine tumors and pancreatic cysts, which can interfere with both exocrine and endocrine functions of the pancreas. Diabetes is an uncommon complication of VHL syndrome. Purpose: This study aims to summarize the various mechanisms of diabetes in VHL syndrome by reporting two cases and conducting a literature review. Methods: We analyzed the clinical and imaging data of two patients with VHL syndrome and diabetes. Additionally, we reviewed the existing literature to explore the clinical diversities and management strategies for VHL syndrome complicated with diabetes. Results: The first patient presented with liver metastasis of pancreatic neuroendocrine tumor and multiple pheochromocytoma. After surgery, the patient’s diabetic control improved, as evidenced by a significant reduction in insulin dosage. This indicates a potential insulin resistance due to elevated metanephrine levels prior to surgery and partial insulin deficiency caused by distal pancreatectomy. The second patient had multiple hemangioblastomas, as well as multiple pancreatic cysts and positive pancreatic islet autoantibodies. Diabetes in this case may be attributed to pancreatic lesions and the coexistence of autoimmune insulitis. A literature review of other patients with VHL combined with diabetes revealed multiple mechanisms, including increased catecholamine levels, pancreatic lesions, surgical removal of pancreatic tissue, endocrine treatment, and possibly the coexistence of autoimmune insulitis. Conclusion: VHL syndrome complicated with diabetes involves diverse mechanisms.
6 August 2022 in Diabetes, Metabolic Syndrome and Obesity
Background: Bariatric surgery is an effective therapy for type 2 diabetes mellitus (T2DM) and obesity. Euglycaemic ketoacidosis (EKA) has been reported in patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors after bariatric surgery. Cases of T2DM complicated with EKA without SGLT2 inhibitors after bariatric surgery are rarely reported. Purpose: To present a case report of a T2DM patient (without SGLT2 inhibitor use) who developed EKA soon after laparoscopic sleeve gastrectomy. Methods: Clinical records and interviews were used. Results: A 35-year-old female patient was diagnosed with T2DM and obesity. The patient underwent laparoscopic sleeve gastrectomy to lose weight and control her blood glucose levels. Her daily fluid intake was 800– 1000 mL, and her daily caloric intake was less than 500 kcal during the first days after the surgery. She was prescribed degludec insulin, metformin and dulaglutide and her blood sugar was lower than 13.9 mmol/L. On postoperative Day 6, the patient complained of fatigue and vomiting. Blood gas analysis and urine analysis supported the diagnosis of ketoacidosis. Fluid resuscitation, insulin and glucose were administered to the patient immediately. On postoperative Day 8, the patient recovered without any symptoms. Conclusion: We report an extremely rare case of T2DM in which the patient developed EKA after laparoscopic sleeve gastrectomy owing to extremely low-calorie intake and dehydration. Physicians should be on alert for ketoacidosis in patients with T2DM after bariatric surgery with an euglycaemic status, even without the use of SGLT2 inhibitors or the presence of stresses, such as infection. Level V: Opinions of respected authorities, based on descriptive studies, narrative reviews, clinical experience, or reports of expert committees.
Background: Inavolisib, a recently approved phosphatidylinositol 3-kinase α (PI3Kα) inhibitor for advanced breast cancer, carries a notable risk of hyperglycemia. Despite this established, on-target adverse effect, clinical endocrinologists often lack sufficient awareness regarding both the risk profile and the specific management strategies required for Inavolisib-induced hyperglycemia. The objective of this report is to describe a patient with fulminant-like diabetes accompanied by Hyperosmolar Hyperglycemic State (HHS) following Inavolisib administration. Case presentation: A 59-year-old female patient with metastatic breast cancer developed rapid-onset and severe hyperglycemia (blood glucose: 48.0 mmol/L at emergency presentation) progressing to HHS within 72 hours of initiating Inavolisib therapy. She presented with fatigue but showed no evidence of ketoacidosis. She had no personal or family history of diabetes mellitus and multiple prior random blood glucose measurements were within normal range. Admission laboratory findings included glycated hemoglobin A1c (HbA1c) 5.7% (reference: 4.0-6.0%), fasting plasma glucose 8.6 mmol/L, fasting insulin 41.5 μU/mL (reference: 2.6–24.9 μU/mL), and fasting C-peptide 10.2 ng/mL (reference: 1.1–4.4 ng/mL), Diabetes-related autoantibodies (ICA, GADA, IAA) were negative. After discontinuation of Inavolisib and administration of intensive insulin therapy, the patient’s hyperglycemia resolved rapidly. Conclusion: Inavolisib-induced hyperglycemia may occur abruptly after treatment initiation and can rapidly progress to severe hyperglycemic emergencies such as HHS, even in patients without known dysglycemia. Normal baseline glycemic indices do not reliably exclude the risk of severe toxicity. Early metabolic assessment, close glucose monitoring, prompt interruption of inavolisib when clinically indicated, and rapid insulin-based management are essential for timely recognition and safe clinical care.
Background: Hypothyroidism is a prevalent endocrine disorder capable of affecting multiple organ systems. While somatic symptoms are common, prominent neuropsychiatric manifestations such as visual hallucinations and cognitive deficits are exceptionally rare as an initial presentation. This atypical clinical picture frequently leads to misdiagnosis as primary psychiatric disorders or neurodegenerative conditions. Case Presentation: We report the case of a 75-year-old male who presented with a three-month history of complex visual hallucinations and progressive cognitive decline. The hallucinations were notably dependent on environmental light. Initial assessments raised concerns about the neurodegenerative process. However, laboratory investigations revealed severe autoimmune hypothyroidism with high titers of anti-thyroid antibodies. Following timely levothyroxine replacement therapy, the patient achieved complete remission of visual hallucinations and significant cognitive recovery. Conclusions: This case illustrates that severe hypothyroidism can manifest as a reversible metabolic encephalopathy mimicking dementia. It underscores the importance of screening for thyroid dysfunction in elderly patients presenting with unexplained acute neuropsychiatric symptoms to ensure appropriate management.